The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease

Autor: Jianfeng Bao, Wengang Li, Jun Li, Zhongping Duan, Yongning Zhou, Shaojie Xin, Jia Shang, Minghua Su, Liaoyun Zhang, Huiguo Ding, Huichun Xing, Liang Qiao, Shumei Lin, Shuchen Li, Xinhua Luo, Jingmin Zhao, Hui Zhuang, Xiaoyuan Xu, Yuemin Nan, Hongsong Chen, Yuguo Zhang, Weize Zuo, Hong Ren, Ying Han, Li Yang, Xiaoguang Dou, Jing Wu, Lai Wei, Jinhui Yang, Jingfeng Liu, Rongkuan Li, Tao Han, Yongjian Zhou, Xinxin Zhang, Ming Yan, Bingyuan Wang, Jiming Yang, Jie Li, Yu Chen, Yanyan Yu, Shourong Liu, Shousong Zhao, Yuexin Zhang, Jian-Gao Fan, Li Shi, Yufang Li, Peng Hu, Lingyi Zhang, Zhili Wen, Huanwei Zheng, Jihong An, Jinghang Xu, Yuan Huang, Yanhang Gao, Huiying Rao, Yongfeng Yang, Lungen Lu, Qinghua Lu, Jiaji Jiang, Rongqi Wang, Wanhua Ren, Biao Wu, Xiong Ma, Jidong Jia, Yan Huang, Ying’an Jiang

Publikováno v: Journal of hepatology. 75(2)

Fatty liver disease associated with metabolic dysfunction is of increasing concern in mainland China, the world's most populous country. The incidence of fatty liver disease is highest in China, surpassing the incidence in European countries and the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::621061f44f25afa6dddc7e761ee4166e
https://pubmed.ncbi.nlm.nih.gov/34968579